Comparative Pharmacology
Head-to-head clinical analysis: MEFOXIN versus MEFOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEFOXIN versus MEFOXIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
MEFOXIN vs MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby inhibiting peptidoglycan cross-linking.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is active against a broad spectrum of gram-positive and gram-negative aerobic and anaerobic bacteria.
1-2 g IV every 6-8 hours; usual dose 1 g IV every 6 hours for uncomplicated infections, 2 g IV every 6-8 hours for severe infections. Maximum 12 g/day.
1-2 g IV every 6-8 hours (Cefoxitin).
None Documented
None Documented
Terminal elimination half-life 0.7-1.1 hours in normal renal function; prolonged to 5-9 hours in severe renal impairment (CrCl <10 mL/min)
Terminal elimination half-life: 0.7-1.1 hours (normal renal function). In anuria: 13-23 hours. Clinical context: Dosing interval adjustment required for CrCl <50 mL/min.
Primarily renal (85% unchanged) via glomerular filtration and tubular secretion; small biliary/fecal (<5%)
Renal: 85% unchanged via glomerular filtration and tubular secretion. Biliary: <1%. Fecal: <1%.
Category C
Category C
Cephamycin Antibiotic
Cephamycin Antibiotic